Impact of uric acid levels on the risk of long-term cardiovascular mortality in patients with type 2 diabetes mellitus

• Published in: Endocrinologia, diabetes y nutricion Vol. 65; no. 6; pp. 335 - 341
• Main Authors: Ilundain-González, Ana Isabel, Gimeno-Orna, José Antonio, Sáenz-Abad, Daniel, Pons-Dolset, Jordi, Cebollada-Del Hoyo, Jesús, Lahoza-Pérez, María Del Carmen
• Format: Journal Article
• Language: English; Spanish
• Published: Spain 01.06.2018
• Subjects: Aged; Cardiovascular Diseases - blood; Cardiovascular Diseases - complications; Cardiovascular Diseases - mortality; Diabetes Complications - blood; Diabetes Complications - mortality; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Female; Humans; Male; Middle Aged; Prospective Studies; Risk Assessment; Time Factors; Uric Acid - blood; Ácido úrico; Mortalidad; Type 2 diabetes mellitus; Uric acid; Diabetes tipo 2; Mortality
• ISSN: 2530-0172; 2530-0180
• DOI: 10.1016/j.endinu.2018.01.004

Hyperuricemia is associated to cardiovascular disease. However, the contribution of uric acid (UA) to cardiovascular mortality in diabetic patients is controversial. To assess the impact of UA levels on the risk of cardiovascular mortality risk in a cohort of patients with type 2 diabetes mellitus (T2DM). A prospective cohort study on outpatients with T2DM. The clinical endpoint was cardiovascular death. Anthropometric, demographic, clinical, and biochemical variables were collected, including UA levels, urinary albumin excretion and estimated glomerular filtration rate. The independent contribution of UA levels to cardiovascular mortality was assessed using multivariate Cox regression models, progressively adjusted for potential confounders. A total of 452 patients with a mean age of 65.9 (SD 9.5) years were enrolled. Mean UA level was 4.2mg/dL. Quartiles of UA levels were Q1 < 3.3; Q2: 3.3-4.2; Q3: 4.3-5.1; Q4 > 5.1mg/dL. UA levels significantly correlated with estimated glomerular filtration rate (Rho=-0.227; p<0.001). During a median follow-up time of 13 years, cardiovascular mortality rates were higher in Q4 of the UA distribution (Q1: 10.7; Q2: 11.7; Q3: 10.7; Q4: 21.6 per 1000 patient-years; p = 0.027). UA was a predictor of cardiovascular mortality in the univariate analysis (HR1mg/dL = 1.30; p=0.002), but not in a multivariate analysis adjusted for urinary albumin excretion and eGFR (HR1mg/dL=1.20; p=0.12). High UA levels are associated to cardiovascular mortality in patients with T2DM. However, the role of UA may be mediated by impaired kidney function in patients with hyperuricemia.